MedTrace Logo

A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

NCT01960010 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 403

Last updated 2019-08-19

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of MIM-D3 Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye.

Conditions

  • Dry Eye Syndromes

Interventions

DRUG

MIM-D3 Ophthalmic Solution

1% MIM-D3 dosed BID

DRUG

Vehicle

Vehicle dosed BID

Sponsors & Collaborators

  • Mimetogen Pharmaceuticals USA, Inc.

    lead INDUSTRY

Principal Investigators

  • Garth Cumberlidge, PhD · Mimetogen Pharmaceuticals USA, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01960010 on ClinicalTrials.gov